Alpha-lipoic acid has a reputation as one of the gentler supplements, and that reputation is mostly earned, but “mostly” is doing real work in that sentence if you take thyroid medication, insulin, or are being treated for cancer.
Quick answer: In trials at 300 to 600 mg per day, alpha-lipoic acid (ALA) was generally well tolerated, with nausea, stomach upset, and rash as the most common complaints. The concerns that deserve a conversation before you buy are additive blood sugar lowering with diabetes medicines, possible effects on thyroid hormone levels, interference with chemotherapy and radiation, and a rare autoimmune reaction that causes severe low blood sugar.
Common side effects in the trials
Pooled data from the randomized trials, which together include a few thousand participants mostly taking 600 mg daily for weeks to months, show a side effect profile that is not dramatic. Nausea was the most frequently reported, and it increased with dose: in a trial comparing 600, 1,200, and 1,800 mg per day, nausea and vomiting were considerably more common at the two higher doses. Other reports include heartburn, abdominal discomfort, dizziness, headache, and skin rash or itching. A distinctive sulfur-like body or urine odor is sometimes mentioned, which makes chemical sense given ALA’s two sulfur atoms.
Dropout rates due to side effects in most trials were low at 600 mg. That is the dose context for most of what follows; higher amounts are a different conversation. The dosage and timing article covers what the trials used.
Blood sugar: the interaction most people underestimate
ALA is studied specifically because it can increase glucose uptake and may lower fasting glucose and insulin resistance markers in some people. That is also exactly why it can be a problem when stacked on top of medicines that do the same thing. The ALA and blood sugar article covers the evidence; this is the safety side of the same coin.
Hypoglycemia warning: Combining any blood-sugar-active supplement with insulin, sulfonylureas, or other glucose-lowering medicines can push glucose too low. Symptoms include shakiness, sweating, confusion, and a fast heartbeat. Do not add a supplement to a medication plan without your prescriber’s knowledge.
The medicines where this matters most are insulin in any form, sulfonylureas (glipizide, glyburide, glimepiride), and meglitinides (repaglinide, nateglinide). Metformin alone rarely causes hypoglycemia, but it is often combined with the others. People who have adjusted their doses carefully over months can find that adding a supplement pushes them into readings they have not seen before, especially overnight or between meals.
Insulin autoimmune syndrome
This one is rare, and it is worth knowing about precisely because it is rare enough that most people have never heard of it. Insulin autoimmune syndrome (sometimes called Hirata disease) happens when the body produces antibodies against its own insulin. The antibodies bind insulin and then release it unpredictably, causing episodes of severe low blood sugar that do not line up with meals or medication timing.
Case reports and case series have linked it to compounds containing sulfhydryl groups, and ALA is one of them. Most reported cases have been in people of Japanese or Korean ancestry who carry a particular immune gene variant (HLA-DR4 subtypes), though cases in other populations exist. It typically resolves after stopping the trigger. If you develop unexplained low blood sugar after starting ALA, particularly if you are not on insulin or a sulfonylurea, that is a prompt call to your clinician, not a reason to push through. A PubMed search on ALA and insulin autoimmune syndrome will show the case literature.
Thyroid medication and thyroid function
ALA appears to affect the conversion of thyroxine (T4) to the more active triiodothyronine (T3). Small human and animal studies have reported lower T3 levels with ALA supplementation. The practical consequence is that if you take levothyroxine for hypothyroidism, ALA could in principle reduce how much active hormone you end up with, even if you keep taking the same levothyroxine dose.
The evidence here is thin, not alarming. But it is specific enough that most pharmacist references list the interaction and suggest separating ALA from levothyroxine by several hours and checking thyroid labs after starting. If you have an underactive thyroid, this is a reason to involve whoever manages your thyroid, not to self-manage. Thyroid dysfunction and metabolic syndrome overlap often enough that it comes up; the metabolic syndrome guide touches on that.
Chemotherapy and radiation
ALA is an antioxidant. Several chemotherapy agents and radiation therapy work partly by generating oxidative damage in cancer cells. Whether antioxidant supplements blunt treatment is debated and depends on the agent, but the common oncology position is to avoid them during active treatment unless the oncologist has specifically approved. Some oncologists have studied ALA for chemotherapy-related neuropathy; a reasonably sized trial of oral ALA for platinum-based chemotherapy neuropathy found no benefit and high dropout. If you are in cancer treatment, your oncology team decides this, full stop.
Alcohol, thiamine, and other cautions
Case reports describe worsened thiamine (vitamin B1) deficiency symptoms when ALA was taken by people who drink heavily or are otherwise thiamine-deficient. The mechanism is not fully understood. If you drink heavily or have had bariatric surgery, mention it.
ALA chelates (binds) some metals. This is sometimes marketed as a benefit, but it also means ALA could in theory reduce absorption of iron or zinc supplements if taken together, and interactions with other chelating drugs are not well studied. Spacing is a reasonable precaution.
Pregnancy and breastfeeding data are limited. Most references advise against supplemental doses during pregnancy and lactation simply because safety has not been established, not because harm has been shown. Pediatric safety data are also sparse.
Because oral ALA absorbs better on an empty stomach and some people find that uncomfortable, a fair number of the stomach complaints in real life are a timing issue rather than a drug issue. The MedlinePlus alpha-lipoic acid page keeps a running interaction list that is updated more often than any supplement article.
What a label will and will not warn you about
US supplement labels are not required to list interactions. You may see a generic “consult your healthcare provider” line and nothing about thyroid, insulin, or chemotherapy. Dose per capsule and per day, the form (racemic versus R-ALA, discussed in R-ALA vs. regular ALA), and a third-party testing seal are the parts of the label worth reading. Metabolic Clarity Labs sells berberine, which carries its own interaction list; hold MCL’s labeling to the same standard you would hold anyone’s. The supplements for metabolic syndrome hub summarizes the interaction profile of each supplement people in this situation commonly ask about.
Questions to bring to your appointment
- I take (list each diabetes medicine). If I added ALA, which of these has real hypoglycemia potential, and what glucose reading should make me stop and call?
- I take levothyroxine. How many hours apart should they be, and would you want a TSH and free T3 or T4 recheck at six to eight weeks?
- Am I on, or scheduled for, any treatment where an antioxidant supplement is a concern?
- Given my family background, is insulin autoimmune syndrome something to be aware of, and what would its symptoms look like for me?
- I take iron (or zinc). Should ALA be separated from it?
- If I get nausea at 600 mg, is splitting the dose or lowering it a reasonable thing to try, or a reason to stop?
ALA’s side effect list is short, and that is accurate. Its interaction list is also short, but the items on it are not minor, and two of them, thyroid and blood sugar, involve medicines that people with metabolic syndrome very commonly take. The neuropathy article covers the population where ALA has the most evidence and, not coincidentally, the most medication overlap.
About the author: Charles Kirkland is the founder of Metabolic Clarity Labs and author of The Journey Back. He is not a physician. This is general education, not a medically reviewed treatment plan.
Sources checked October 29, 2026. Discuss personal decisions with a qualified clinician or pharmacist. Do not start, stop, or change prescribed treatment based on this article.
Leave a Reply